Nicolas Bardonnet – General Manager, Promega France
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
With a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions to life scientists in academic, industrial and government settings. Founded in 1978 byWilliam Linton in Madison, Wisconsin, Promega has branches in 16 countries and more than 50 global distributors serving 100 countries. They have eight European branches. Promega has been present in France since 1982 and are responsible for operations in Greece, Egypt as well as North Africa and French speaking African countries. France hosts both their European application centre as well as the European training centre, which offers a wide range of courses in molecular biology, cell biology, proteomics and genetic identity.
Contact
Address: 24 Chemin des Verrières, 69260 Charbonnières-les-Bains, France
Tel: +33 4 37 22 63 48
Web: france.promega.com
Facebook: https://www.facebook.com/promegafrance
Twitter (@PromegaFR): https://twitter.com/PromegaFR
LinkedIn: https://www.linkedin.com/company/promega
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
Nicolas Bardonnet, general manager of Promega France, reveals how France hosts both their European application laboratory and European training centre, offering a wide range of courses in molecular biology, cell…
Dominique Pezziardi oversees International Commercial Operations for Stallergenes Greer, a global biotechnology company specialising in allergy therapeutics. With more than 1,200 employees globally – over 600 based in France –…
Erick Lelouche has served as President of Lyonbiopôle since February 2025, bringing more than 35 years of experience in the pharmaceutical industry across Pfizer and Boehringer Ingelheim, spanning human and…
This conversation with Bruno Dubois offers a clear, experience-driven perspective on how Alzheimer’s disease is being redefined, from diagnosis and biomarkers to prevention and early intervention. Drawing on decades at…
Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With…
MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and…
Estelle Fruchet, General Manager of Shionogi France since September 2024, brings 25 years of pharmaceutical experience spanning major organisations including Roche, Gilead, and Novartis Gene Therapies. A pharmacist by training…
Genethon sits at the forefront of a fast-accelerating moment in gene medicine, where decades of foundational research are now translating into clinical progress across rare liver, neuromuscular, immune and ophthalmic…
Norgine is redefining what a mid-sized European specialist can achieve, shifting from its gastroenterology heritage into a broader mix of consumer health, women’s health and rare diseases. These changes are…
Frederic Collet, Chairman of FIAC (La Filière Intelligence Artificielle et Cancers), leads a pioneering public-private consortium bringing together nine of the world’s most innovative oncology companies with France’s public health…
Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation.…
Jazz Pharmaceuticals’ footprint in France has accelerated over recent years, driven by a sharper focus on rare and complex diseases, a sequence of strategic acquisitions and a growing role in…
Alnylam is reshaping therapeutic possibilities through RNA interference, and France has become one of the strategic environments where this shift is most visible. In this interview, Jean-Baptiste Caquelin reflects on…
See our Cookie Privacy Policy Here
